7-OH-DPAT-induced inhibition of norepinephrine release in PC12 cells

被引:10
作者
Chu, E
Chu, J
Socci, RR
Chu, TC
机构
[1] Morehouse Sch Med, Dept Pharmacol & Toxicol, Atlanta, GA 30310 USA
[2] Univ Georgia, Athens, GA 30602 USA
[3] Spelman Coll, Atlanta, GA 30314 USA
关键词
norepinephrine release; D-2/D-3; receptors; 7-OH-DPAT; cAMP/cGMP mRNA; immunocytochemistry; immunoblotting intracellular Ca2+; PC12; cells;
D O I
10.1159/000074976
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate mechanisms of suppression of norepinephrine release by 7OH-DPAT, a dopamine D-2/D-3 receptor agonist, in PC12 cells pretreated with nerve growth factor (NGF). 7-OH-DPAT caused inhibition of basal and K+-evoked norepinephrine release, which could be blocked by pretreatment with raclopride, a D-2/D-3 receptor antagonist. Moreover, dopamine D-2 and D-3 receptors were identified by immunocytochemistry. Expression of D-2, D-3, and D-4 mRNAs and their proteins were detected using RT-PCR and immunoblotting. Furthermore, 7-OH-DPAT produced no change in cGMP levels; however, 7-OH-DPAT inhibited forskolin-stimulated cAMP accumulation that was antagonized by pretreatment with raclopride. In addition, 7-OH-DPAT inhibited carbachol-induced Ca2+ transient, conversely, 7-OH-DPAT had no effect on 4-aminopyridine-induced Ca2+ transient. Taken together, suppression of cAMP accumulation and calcium mobilization by 7-OH-DPAT is involved in the inhibition of norepinephrine release through activation of dopamine D-2/D-3 receptors. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 46 条
[1]   Regulation of stimulatory adenylyl cyclase signaling during forskolin-induced differentiation of mouse neuroblastoma x rat glioma (NG1O8-15) cells [J].
Ammer, H ;
Schulz, R .
NEUROSCIENCE LETTERS, 1997, 230 (03) :143-146
[2]   Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells:: Distinct Gα and Gβγ requirements [J].
Banihashemi, B ;
Albert, PR .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (10) :2393-2404
[3]  
BOUNDY VA, 1993, J PHARMACOL EXP THER, V264, P1002
[4]  
Chu E, 2000, J PHARMACOL EXP THER, V293, P710
[5]   Potential sites of action of TNPA: A dopamine-2 receptor agonist [J].
Chu, E ;
Chu, TC ;
Potter, DE .
EXPERIMENTAL EYE RESEARCH, 1999, 69 (06) :611-616
[6]   Potential mechanisms of moxonidine-induced ocular hypotension: Role of norepinephrine [J].
Chu, TC ;
Socci, RR ;
Ogidigben, MJ ;
Potter, DE .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1997, 13 (06) :489-496
[7]  
CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433
[8]   DOPAMINERGIC REGULATION OF DOPAMINE RELEASE FROM PC12 CELLS VIA A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN [J].
COURTNEY, ND ;
HOWLETT, AC ;
WESTFALL, TC .
NEUROSCIENCE LETTERS, 1991, 122 (02) :261-264
[9]   Human dopamine D3 receptors mediate mitogen- activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism [J].
Cussac, D ;
Newman-Tancredi, A ;
Pasteau, V ;
Millan, MJ .
MOLECULAR PHARMACOLOGY, 1999, 56 (05) :1025-1030
[10]  
Davila V, 2003, J NEUROSCI, V23, P5693